Asthma

The WAYFINDER trial is the first to demonstrate the positive impact of the thymic stromal lymphopoietin antagonist on steroid-dependent severe asthma.

Data from the global RAPID registry provide real-world support for dupilumab efficacy in youths and adults with uncontrolled asthma and with or without CRS and/or nasal polyposis.

The chronotherapeutic approach aligns treatment with peak glucocorticoid sensitivity, so may mitigate onset of the inflammatory cascade that triggers nocturnal exacerbations.

The KALOS and LOGOS registration trials in patients with uncontrolled asthma compared the triple fixed dose BGF with dual combination therapy.

The FDA set the Prescription Drug User Fee Act (PDUFA) date for December 16, 2025.

AAAAI 2025. One study found the 2 newer biologics have been prescribed more frequently while the other suggests asthma treatment may not be optimal or even consistent.

AAAAI 2025. Early postnatal antibiotic exposure in full-term infants was associated with a 30% increased risk of childhood asthma, according to a new study.

The investigational molecule with “JAK-inhibitor-like efficacy and IL4/IL13-like safety,” was cleared in Q4 2024 by the FDA for an IND application, the company said.

Albuterol/budesonide (Airsupra) has now proven effective as novel combination as-needed rescue medication for adults with asthma regardless of disease severity.

A new study shows that higher vaccination rates were associated with a decrease in the prevalence of parent-reported asthma symptoms in children.

The high potency IL-5 inhibitor can be administered every 6 months, offering a convenient alternative to other biologic agents for appropriate patients with severe asthma.

Adults with undiagnosed asthma or COPD who were randomly detected and assigned to specialist or usual care all had improved outcomes at 1 year, Canadian authors reported.

The company will present new data on effects of tezepelumab in COPD and of inhaled triple therapy Breztri on cardiopulmonary outcomes in COPD.

Your daily dose of the clinical news you may have missed.

Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.

The additional indication for benralizumab was supported by data from the phase 3 TATE trial.

The monthly out of pocket cap applies to all BI inhalers and goes into effect on June 1, 2024.

Your daily dose of the clinical news you may have missed.

New data presented at AAAAI 2024 sheds light on real-world patterns of biologic use in a diverse patient population with severe asthma.

AAAAI 2024. Indoor mouse and cockroach, but not cat and dog, allergen exposure were associated with URI outcomes among children with asthma.

AAAAI 2024. Patients with asthma who received dupilumab plus medium-dose ICS had improved lung function and asthma control vs those who received placebo plus high-dose ICS.

Your daily dose of the clinical news you may have missed.

The risk of cough and asthma in persons with severe depression was 3.32 times and 2.84 times higher, respectively, than that in those without depression, reported researchers.

Past month use of cannabis was associated with 43% greater odds of asthma than no use of the drug; odds were 2-fold greater with use of blunts.

New data suggest that dupilumab is safe for long-term use among patients with moderate-to-severe asthma or OCS-dependent severe asthma.

The risk of asthma and poor outcomes was even greater among children with both conditions than among adults in this first study to compare the 2 populations.

Use of dupilumab also eliminated the need for use of a rescue inhaler in more than one-third of treated patients and the number of inhalations needed for others.

Your daily dose of the clinical news you may have missed.

A new meta-analysis found prevalence of asthma higher in countries with better air quality, higher income status, and health care access.

Your daily dose of the clinical news you may have missed.